Effect of Growth Hormone on Insulin Signaling in Muscle Tissue

NCT ID: NCT00477997

Last Updated: 2009-04-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the effects of a physiological bolus of growth hormone on insulin signaling pathways in muscle tissue in healthy lean men.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Saline bolus + OGTT

Group Type PLACEBO_COMPARATOR

Physiological Bolus of Growth Hormone

Intervention Type DEVICE

0,5 mg Norditropin

2

GH-bolus and OGTT

Group Type OTHER

Physiological Bolus of Growth Hormone

Intervention Type DEVICE

0,5 mg Norditropin

3

GH-bolus

Group Type OTHER

Physiological Bolus of Growth Hormone

Intervention Type DEVICE

0,5 mg Norditropin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physiological Bolus of Growth Hormone

0,5 mg Norditropin

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Healthy
* Age between 18 and 30 years
* BMI ≤ 26

Exclusion Criteria

* Known present disease including diabetes mellitus
* BMI \> 26
* Uses any medication
* Consumes \> 21 units of alcohol per week
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aarhus University Hospital

OTHER

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aarhus University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens Otto L Jørgensen, MD, DMSc

Role: PRINCIPAL_INVESTIGATOR

Department M (endocrinology and diabetes), Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department M (endocrinology and diabetes)

Aarhus, Aarhus, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Krusenstjerna-Hafstrom T, Madsen M, Vendelbo MH, Pedersen SB, Christiansen JS, Moller N, Jessen N, Jorgensen JO. Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PLoS One. 2011 May 3;6(5):e19392. doi: 10.1371/journal.pone.0019392.

Reference Type DERIVED
PMID: 21559284 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MM-GH-20070052

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Growth Hormone and Glucose Metabolism
NCT00929799 COMPLETED PHASE4
GH and Cardiovascular Risk Factors
NCT01877512 COMPLETED PHASE4